Lombard Medical’s Endovascular Product Portfolio Presented at Scientific Sessions of the 39th Annual Charing Cross International Symposium

Get Instant Instagram Followers and Likes with GetInsta

GetInsta App is 100% safe and secure to get benefits from online smart feature plans. There are lots of reliable and smart feature explorations to achieve your objectives. Learn more!

Philips Introduces Integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3

The integration provides the opportunity for monitoring during image-guided procedures on the Philips Image Guided Therapy System – Azurion, improving workflow with comprehensive patient records that support timely clinical decision-making during interventional cardiology procedures and beyond.

Lawson Health Research Institute Found Simple Device Improves Care After Kidney Transplantation

The geko™ device, manufactured by Sky Medical Technology Ltd and distributed in Canada by Trudell Healthcare Solutions Inc., is a muscle pump activator that significantly improves blood flow by stimulating the body’s ‘muscle pumps.’

 

Portfolio of endovascular stent graft systems, Altura® and Aorfix™ announced at London, United Kingdom, conference

Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that its portfolio of endovascular stent graft systems, Altura® and Aorfix™, were featured in scientific presentations at the 39th annual Charing Cross International Symposium in London on April 25 – 26.

Altura Presentations

Altura clinical data combined from two prospective international multicentre studies were presented at Charing Cross in a paper titled ‘A new low-profile device approach – results out to 5 years’ by Prof. Dainis Krievins, of the Paul Stradins University Hospital, Riga, Latvia, on behalf of the study investigators.

Key findings of the 90-patient dataset were as follows:

  • Technical success was 99%
  • Percutaneous access was achieved in 57% of patients
  • Only 21% of patients required general anaesthesia
  • There were no abdominal aortic aneurysm (AAA)-related deaths over the period of follow-up
  • No patients suffered sac expansion
  • Mean follow-up of 12.4 months

Prof. Krievins commenting on the results said, “Altura is impressively easy to use based on its 14Fr profile, repositionability and avoidance of cannulation. The performance of the stent graft, as demonstrated in the clinical data, is equivalent to contemporary grafts that do not share these advantages.”

In a second presentation about the clinical utility of Altura, Paul Hayes, vascular surgeon at Addenbrookes Hospital, Cambridge, UK, used a video case study to demonstrate the ease of use of the system. Hayes cited Altura’s unique retrograde limb deployment with built-in contrast injection in aiding predictable, shorter, procedure times.

Lombard is initiating a European registry for the CE-marked Altura system which is now available commercially in the U.K. and certain other international markets. The Altura system represents a paradigm shift in endograft design offering a simple and predictable option for standard AAA anatomy. Delivered via an ultra-low profile 14F catheter, Altura allows for repositioning during deployment and accurate graft placement at each renal artery enabling physicians to utilize all of the available aortic neck. It also eliminates the need for cannulation that results in a simple, safe and consistent deployment with predictable, shorter procedure times. With just six product sizes, the Altura system allows the majority of patients to be treated quickly with minimal hospital stay and recovery times.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles